"Japan Pharmaceuticals & Healthcare Report Q1 2016" Published

Japan's delayed entry into the medical tourism industry will see the country facing significant headwinds in developing the sector. Leading medical tourism hubs in the Asia Pacific region, such as Malaysia and Thailand, have already firmly established their sectors, offering medical treatments at a significantly lower cost. Moreover, Japan faces distinct challenges, including the country's considerable distance from the growing South East Asia markets and the limited inclusion of medical tourism in the business plans of the country's healthcare providers.

Headline Expenditure Projections

Pharmaceuticals: JPY11,239bn (USD106bn) in 2014 to JPY11,490bn (USD95bn) by 2015 with a year-on-year (y-o-y) growth of 2.2% in local currency terms and -10.5% in USD terms. The contraction in the US dollar amount is due to the strengthening of the dollar against the yen.
Healthcare: JPY50,277bn (USD475bn) in 2014 to JPY51,305bn (USD424bn) in 2015 with a y-o-y growth of 2.0% in local currency terms and-10.7% in USD terms. Healthcare spending revised downwards due to new data from the World Health Organization. The lower US dollar amount is driven by the weakening of the yen against the dollar.

Full Report Details at
- http://www.fastmr.com/prod/1073110_japan_pharmaceuticals.aspx?afid=302

Risk/Reward Index

Japan's continues to be ranked as the most attractive region according to our Pharmaceutical Risk/Reward Index, scoring 73.3 out of 100 in Q415, significantly ahead of peers such as Australia (65.8) and South Korea (66.2) as well as the region's average at 52.4. This is driven by the country's high market expenditure scoring (18.0 out of 20.0) as well as a high spending per capita score of (10.8 out of 12.0). However, dragging down the country's score includes a declining population (population growth score of 1.0 out of 5.0). In addition, we highlight that the country's score has been lowered due to the weakness in the Japanese Yen, which translates into a lower value returns in US dollars.

The Japan Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Japan Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Japan pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Japan, to test other views - a key input for successful budgeting and strategic business planning in the Japanese pharmaceutical and healthcare market.
* Target business opportunities and risks in the Japanese pharmaceutical and healthcare sector

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Kenya Pharmaceuticals & Healthcare Report Q1 2016
- Thailand Pharmaceuticals & Healthcare Report Q1 2016
- Pakistan Pharmaceuticals & Healthcare Report Q1 2016
- Argentina Pharmaceuticals & Healthcare Report Q1 2016
- Croatia Pharmaceuticals & Healthcare Report Q1 2016